# HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

> **NCT03135184** · NA · UNKNOWN · sponsor: **HDL Therapeutics** · enrollment: 6 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia
- HoFH

## Interventions

- **DEVICE:** HDL Therapeutics PDS-2 System

## Key facts

- **NCT ID:** NCT03135184
- **Lead sponsor:** HDL Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-26
- **Primary completion:** 2019-01-07
- **Final completion:** 2019-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2019-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03135184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03135184, "HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03135184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*